Gilder Gagnon Howe Co buys $72,113,744 stake in Flexion Therapeutics Inc (FLXN)

Flexion Therapeutics Inc (FLXN) : Gilder Gagnon Howe Co scooped up 927,625 additional shares in Flexion Therapeutics Inc during the most recent quarter end , the firm said in a disclosure report filed with the SEC on Aug 1, 2016. The investment management firm now holds a total of 4,307,870 shares of Flexion Therapeutics Inc which is valued at $72,113,744.Flexion Therapeutics Inc makes up approximately 1.33% of Gilder Gagnon Howe Co’s portfolio.

Other Hedge Funds, Including , California State Teachers Retirement System boosted its stake in FLXN in the latest quarter, The investment management firm added 8,957 additional shares and now holds a total of 38,813 shares of Flexion Therapeutics Inc which is valued at $649,730.Alps Advisors Inc boosted its stake in FLXN in the latest quarter, The investment management firm added 6,078 additional shares and now holds a total of 30,301 shares of Flexion Therapeutics Inc which is valued at $517,844. Simplex Trading added FLXN to its portfolio by purchasing 408 company shares during the most recent quarter which is valued at $6,487.Cutler Group Lp boosted its stake in FLXN in the latest quarter, The investment management firm added 6,795 additional shares and now holds a total of 14,795 shares of Flexion Therapeutics Inc which is valued at $231,246. Flexion Therapeutics Inc makes up approx 0.02% of Cutler Group Lp’s portfolio. Bnp Paribas Arbitrage Sa added FLXN to its portfolio by purchasing 734 company shares during the most recent quarter which is valued at $11,928.

Flexion Therapeutics Inc opened for trading at $16.9 and hit $19.05 on the upside on Thursday, eventually ending the session at $17.25, with a gain of 3.05% or 0.51 points. The heightened volatility saw the trading volume jump to 6,36,188 shares. Company has a market cap of $372 M.

Many Wall Street Analysts have commented on Flexion Therapeutics Inc. Lake Street Initiated Flexion Therapeutics Inc on Jul 21, 2016 to “Buy”, Price Target of the shares are set at $38.

Flexion Therapeutics Inc. is a specialty pharmaceutical company focused on the development and commercialization of injectable pain therapies. The Company is also focused on anti-inflammatory and analgesic therapies for the treatment of patients with musculoskeletal conditions such as osteoarthritis (OA) a type of degenerative arthritis. The Company’s portfolio of product candidates addresses the OA pain treatment spectrum from moderate to severe pain. The Company’s products include FX006 which is indicated for front line intra-articular (IA) therapy for patients with moderate to severe OA pain; FX007 which is indicated for post-operative pain and FX005 which is indicated for end-stage OA pain. The Company is conducting a pivotal Phase IIb clinical trial of FX006. The Company is conducting preclinical local pharmacology and toxicology experiments of FX007. FX005 has completed its Phase IIa trials.

Comments (0)

Leave a Reply

Your email address will not be published. Required fields are marked *